Business Description
BioStem Technologies Inc
NAICS : 325411
SIC : 2834
ISIN : US0906842002
Total Employee Number:
2Description
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.69 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.51 | |||||
Beneish M-Score | 12.67 | |||||
WACC vs ROIC | ||||||
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.03 | |||||
9-Day RSI | 68.77 | |||||
14-Day RSI | 62.53 | |||||
3-1 Month Momentum % | 7.44 | |||||
6-1 Month Momentum % | -30.07 | |||||
12-1 Month Momentum % | -34.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.98 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 316.45 | |||||
Days Sales Outstanding | 172.19 | |||||
Days Payable | 635.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | 1.06 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.28 | |||||
Operating Margin % | -123.16 | |||||
Net Margin % | -126.76 | |||||
EBITDA Margin % | -113.64 | |||||
FCF Margin % | -45.76 | |||||
OCF Margin % | -45.34 | |||||
ROE % | -64.43 | |||||
ROA % | -36.44 | |||||
ROIC % | -58.92 | |||||
3-Year ROIIC % | 182.35 | |||||
ROC (Joel Greenblatt) % | -335.96 | |||||
ROCE % | -62.59 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 12.86 | |||||
Price-to-Owner-Earnings | 5.98 | |||||
PS Ratio | 5.27 | |||||
PB Ratio | 2.79 | |||||
Price-to-Tangible-Book | 16.04 | |||||
EV-to-EBIT | -4.13 | |||||
EV-to-EBITDA | -4.48 | |||||
EV-to-Revenue | 5.09 | |||||
EV-to-Forward-Revenue | 1.33 | |||||
EV-to-FCF | -11.13 | |||||
Price-to-Projected-FCF | 1.5 | |||||
Earnings Yield (Greenblatt) % | -24.21 | |||||
FCF Yield % | -8.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BSEM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
BioStem Technologies Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.035 | ||
| EPS (TTM) ($) | -1.04 | ||
| Beta | 0.3112 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.29 | ||
| Volatility % | 87.48 | ||
| 14-Day RSI | 62.53 | ||
| 14-Day ATR ($) | 0.393255 | ||
| 20-Day SMA ($) | 3.6725 | ||
| 12-1 Month Momentum % | -34.42 | ||
| 52-Week Range ($) | 2.251 - 8.4 | ||
| Shares Outstanding (Mil) | 17.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioStem Technologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioStem Technologies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 62 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-11 07:00 | 4.18 (+1.09%) | ||
| Micro-Cap Virtual Investor Conference | 2026-08-19 20:15 | 3.15 (+3.62%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | 3.61 (-1.10%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 3.61 (-1.10%) | ||
| Guidance call for 2026 | 2026-06-17 15:00 | 4.15 (+0.81%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 5.08 (+0.50%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 5.08 (+0.50%) | ||
| the 25(th) Annual Needham Virtual Healthcare Conference | 2026-04-13 08:45 | 5.13 (-1.31%) |
Show
Entries
BioStem Technologies Inc Frequently Asked Questions
What is BioStem Technologies Inc(BSEM)'s stock price today?
The current price of BSEM is $4.33. The 52 week high of BSEM is $8.40 and 52 week low is $2.25.
When is next earnings date of BioStem Technologies Inc(BSEM)?
The next earnings date of BioStem Technologies Inc(BSEM) is 2026-11-13 Est..
Does BioStem Technologies Inc(BSEM) pay dividends? If so, how much?
BioStem Technologies Inc(BSEM) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers